Search for: "AMAG Pharmaceuticals, Inc." Results 1 - 9 of 9
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 Oct 2010, 8:15 am by Thomas Anapol
The FDA, as part of its routine monitoring and surveillance program designed to protect consumers from overly aggressive marketing or misleading information about drug and medical device products, has issued a warning letter to AMAG Pharmaceuticals, Inc. concerning its drugs GastroMARK® and Feraheme™ for violating the Federal Food, Drug and Cosmetic Act and for failing to submit a copy of their web pages about the drug to the FDA. [read post]
23 Aug 2011, 11:53 am
AMAG Pharmaceuticals is focused on the development of therapeutic iron to treat iron deficiency anemia. [read post]
16 Feb 2012, 6:00 am by SECLaw Staff
He also traded on other confidential information in 2009 and 2010, purchasing call options in the securities of Arena Pharmaceutical, Inc., and AMAG Pharmaceutical, Inc., respectively, when the firms were engaged in confidential discussions on business transactions with Takeda. [read post]
3 Oct 2011, 1:48 pm by Francis Pileggi
Background The plaintiff, a shareholder of AMAG Pharmaceuticals, Inc., initiated an action to stop AMAG from acquiring Allos Therapeutics, Inc. [read post]
30 Apr 2010, 11:52 am by Sonya Hubbard
 Take a peek at p. 66 of AMAG Pharmaceuticals, Inc. [read post]
30 Apr 2010, 11:52 am by Sonya Hubbard
 Take a peek at p. 66 of AMAG Pharmaceuticals, Inc. [read post]
20 Nov 2020, 5:00 am by John Jascob
AMAG Pharmaceuticals (2013), the First Circuit held that the plaintiffs stated an Item 105 claim where the defendant failed to disclose serious adverse events even though it knew about them. [read post]